Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. This implies the risk of DAPT being erroneously continued after the intended stop date. Objective: The primary objective of this study is to assess the proportion of hospitalized patients treated with DAPT whose treatment deviated erroneously and unintentionally from the guidelines. We also assessed risk factors and the effect of a pharmacist intervention. Methods: All patients admitted to the Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands)...
BACKGROUND: To prevent cardiovascular complications, sometimes double and triple therapy with a vita...
BACKGROUND: Although the benefits of antithrombotic drugs are indisputable to reduce thrombotic even...
Abstract Background Dual antiplatelet therapy (DAPT) is key for preventing ischaemic events post‐per...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
OBJECTIVES Despite guideline recommendations, previous reports, coming mainly from outside Europe...
Background and purposeGuidelines recommend that patients with high-risk TIAs and minor strokes prese...
BackgroundPolypharmacy increases the risk of potentially inappropriate prescribing. STOPP&START ...
Dual antiplatelet therapy (DAPT) is a cornerstone of antithrombotic treatment in patients undergoing...
OBJECTIVES: This study aimed to evaluate the adherence to protocols for the use of reversal agents i...
ObjectivesCHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of ...
Introduction ‘Real world’ bleeding in patients exposed to different regimens of dual antiplatelet th...
Background: Dual antiplatelet therapy (DAPT) is a mainstay treatment for hospital survivors of an ac...
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but ...
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients ...
BACKGROUND: To prevent cardiovascular complications, sometimes double and triple therapy with a vita...
BACKGROUND: Although the benefits of antithrombotic drugs are indisputable to reduce thrombotic even...
Abstract Background Dual antiplatelet therapy (DAPT) is key for preventing ischaemic events post‐per...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2...
OBJECTIVES Despite guideline recommendations, previous reports, coming mainly from outside Europe...
Background and purposeGuidelines recommend that patients with high-risk TIAs and minor strokes prese...
BackgroundPolypharmacy increases the risk of potentially inappropriate prescribing. STOPP&START ...
Dual antiplatelet therapy (DAPT) is a cornerstone of antithrombotic treatment in patients undergoing...
OBJECTIVES: This study aimed to evaluate the adherence to protocols for the use of reversal agents i...
ObjectivesCHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of ...
Introduction ‘Real world’ bleeding in patients exposed to different regimens of dual antiplatelet th...
Background: Dual antiplatelet therapy (DAPT) is a mainstay treatment for hospital survivors of an ac...
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but ...
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients ...
BACKGROUND: To prevent cardiovascular complications, sometimes double and triple therapy with a vita...
BACKGROUND: Although the benefits of antithrombotic drugs are indisputable to reduce thrombotic even...
Abstract Background Dual antiplatelet therapy (DAPT) is key for preventing ischaemic events post‐per...